Abstract
Hepatocellular Carcinoma (HCC) and Colorectal Carcinoma (CRC) are cancers with high incidence and mortality worldwide, both displaying a poor prognosis. Many patients in advanced disease stages are submitted to low response antineoplastic therapies. Tumor microenvironment modulation is also neglected in current targeted therapies. The most prominent epidemiological studies highlight that …